A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Conditions: Herpes Zoster (HZ); Shingles; Infectious Disease Interventions: Biological: JCXH-105; Biological: Active Control (Shingrix) Sponsors: Immorna Biotherapeutics, Inc.; ICON plc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Herpes | Research | Shingles | Shingles (Herpes Zoster) Vaccine | Study | Vaccines | Varicella-Zoster Virus Vaccine